Corifollitropin Alfa + Follitropin beta + oral contraceptive pill pretreatment (Marvelon)

Phase 3Completed
0 views this week 0 watching Active
Interest: 40/100
40
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Infertility, Female

Conditions

Infertility, Female, Polycystic Ovary Syndrome

Trial Timeline

Nov 1, 2017 → Dec 31, 2022

About Corifollitropin Alfa + Follitropin beta + oral contraceptive pill pretreatment (Marvelon)

Corifollitropin Alfa + Follitropin beta + oral contraceptive pill pretreatment (Marvelon) is a phase 3 stage product being developed by Merck for Infertility, Female. The current trial status is completed. This product is registered under clinical trial identifier NCT03197077. Target conditions include Infertility, Female, Polycystic Ovary Syndrome.

What happened to similar drugs?

11 of 20 similar drugs in Infertility, Female were approved

Approved (11) Terminated (4) Active (9)

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03197077Phase 3Completed

Competing Products

20 competing products in Infertility, Female

See all competitors